Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to 47.58%.

  • Ligand Pharmaceuticals' EBITDA Margin rose 415100.0% to 47.58% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.97%, marking a year-over-year increase of 176900.0%. This contributed to the annual value of 13.53% for FY2024, which is 226200.0% down from last year.
  • Ligand Pharmaceuticals' EBITDA Margin amounted to 47.58% in Q3 2025, which was up 415100.0% from 17.73% recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' EBITDA Margin ranged from a high of 66.82% in Q4 2021 and a low of 79.89% during Q1 2025
  • Its 5-year average for EBITDA Margin is 6.32%, with a median of 9.65% in 2024.
  • Its EBITDA Margin has fluctuated over the past 5 years, first tumbled by -1067100bps in 2022, then surged by 637200bps in 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' EBITDA Margin (Quarter) stood at 66.82% in 2021, then crashed by -160bps to 39.89% in 2022, then skyrocketed by 70bps to 11.95% in 2023, then plummeted by -88bps to 22.51% in 2024, then skyrocketed by 311bps to 47.58% in 2025.
  • Its last three reported values are 47.58% in Q3 2025, 17.73% for Q2 2025, and 79.89% during Q1 2025.